Peroxisome Proliferator-Activated Receptors target family landscape: A chemometrical approach to ligand selectivity based on protein binding site analysis

The Peroxisome Proliferator-Activated Receptors (PPARs) are nuclear receptors which over the last couple of years have been the focus of considerable research efforts aiming to identify compounds with well-defined selectivity profiles for the treatment of metabolic diseases. The ligand binding domains (LBD) of the three known PPAR subtypes exhibit between 60 and 70% sequence identity. To gain insight into the structural determinants of selectivity for the PPAR subtypes, a set of 13 crystal structures of PPAR LBD were classified, using the GRID/CPCA approach. As a result, nearly all of the crystal structures of each different PPAR subtype were found clustered in different regions of the CPCA score plots, and hydrophobic as well as steric interactions were identified as the major determinants of PPAR subtypes selectivity. Furthermore, interpretation of the GRID/CPCA model in structural terms led to the identification of LBD regions which could be targeted to improve the selectivity for a given PPAR subtype. Our findings are consistent with published structure–activity relationships for PPAR ligands as well as with site-directed mutagenesis results.

[1]  Mika A. Kastenholz,et al.  GRID/CPCA: a new computational tool to design selective ligands. , 2000, Journal of medicinal chemistry.

[2]  G. Cruciani,et al.  Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D‐QSAR Problems , 1993 .

[3]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[4]  P J Goodford,et al.  A search for specificity in DNA-drug interactions. , 1994, Journal of Molecular Graphics.

[5]  Millard H. Lambert,et al.  Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα , 2002, Nature.

[6]  M Pastor,et al.  A novel strategy for improving ligand selectivity in receptor-based drug design. , 1995, Journal of medicinal chemistry.

[7]  A. Steinmetz,et al.  Binding of ligands and activation of transcription by nuclear receptors. , 2001, Annual review of biophysics and biomolecular structure.

[8]  H. Rami,et al.  Synthetic ligands for PPARγ - review of patent literature 1994 - 1999 , 2000 .

[9]  R. Glen,et al.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.

[10]  N. Blomberg,et al.  Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family , 2001 .

[11]  John P. Overington,et al.  Knowledge‐based protein modelling and design , 1988 .

[12]  T. Halgren.  MMFF VI. MMFF94s option for energy minimization studies , 1999, J. Comput. Chem..

[13]  Millard H. Lambert,et al.  Identification of a series of PPARγ/δ dual agonists via solid-phase parallel synthesis , 2001 .

[14]  G Klebe,et al.  Use of Relibase for retrieving complex three-dimensional interaction patterns including crystallographic packing effects. , 2001, Biopolymers.

[15]  B. Lohray,et al.  (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. , 2001, Journal of medicinal chemistry.

[16]  H. Matter,et al.  Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes. , 2002, Journal of medicinal chemistry.

[17]  M. Faul,et al.  Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. , 2001, Journal of medicinal chemistry.

[18]  K. Umesono,et al.  Alteration of a Single Amino Acid in Peroxisome Proliferator-Activated Receptor-α (PPARα) Generates a PPARδ Phenotype , 2000 .

[19]  J. Macgregor,et al.  Analysis of multiblock and hierarchical PCA and PLS models , 1998 .

[20]  T. Willson,et al.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.

[21]  T. Andersson,et al.  Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA. , 2001, Journal of medicinal chemistry.

[22]  W. Wilkison,et al.  Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. , 2001, Bioorganic & medicinal chemistry letters.

[23]  J. Corton,et al.  Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. , 2000, Annual review of pharmacology and toxicology.

[24]  L. Jendeberg,et al.  Crystal Structure of the Ligand Binding Domain of the Human Nuclear Receptor PPARγ* , 1998, The Journal of Biological Chemistry.

[25]  J. Petrie,et al.  Insulin-sensitising agents: beyond thiazolidinediones , 2002, Expert opinion on emerging drugs.

[26]  Gert Vriend,et al.  Collecting and harvesting biological data: the GPCRDB and NucleaRDB information systems , 2001, Nucleic Acids Res..

[27]  H Matter,et al.  Affinity and selectivity of matrix metalloproteinase inhibitors: a chemometrical study from the perspective of ligands and proteins. , 1999, Journal of medicinal chemistry.

[28]  R. Evans,et al.  Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.

[29]  T. Willson,et al.  The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.

[30]  Gabriele Cruciani,et al.  Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach. , 2002, Journal of medicinal chemistry.

[31]  T. Willson,et al.  Identification of a series of oxadiazole-substituted α-isopropoxy phenylpropanoic acids with activity on PPARα, PPARγ, and PPARδ , 2001 .